The Hermelin Brain Tumor Center is redefining the standard for brain tumor treatment. Today, the chance of long-term survival greater than three years for glioblastoma patients has increased from less than 10 percent to more than 30 percent.

Our patients find compassion and ongoing support from our experienced brain tumor specialists, who offer what every brain tumor patient and their family needs — rapid diagnosis, personalized care and expert treatment.

Donor support has made all the difference.

HENRY FORD HEALTH SYSTEM DEVELOPMENT OFFICE
(313) 876-1031 | henryford.com/development
Thanks to the powerful support of donor funds, Hermelin Brain Tumor Center (HBTC) has pioneered a holistic approach to brain health that focuses on more than attacking tumors. Its state-of-the-art, on-site research enables doctors to understand how tumors behave and function—this goes straight from the lab to doctors and patients who need it the most.

**Beyond the Brain**

HBTC is treating not just the brain but also leading the initiation of groundbreaking therapies, and caring for the whole patient. This means:

**Personalized Medicine**

- Recently launched an advanced precision medicine program to revolutionize cancer care in the greater Midwest. In partnership with Syapse, this will increase access to the best care for all patients through world-class, targeted cancer treatments.
- Thirty tumor specialists at minimum—including radiologists, surgeons, nurses and oncologists—review each case individually to adjust treatments as necessary.
- Individualized, pioneering avatars give doctors the ability to see how the tumor functions in each patient, allowing customized, effective treatment.

**Advances in National Research**

- HBTC is one of six institutions selected nationally to lead the global clinical trial initiative to fight glioblastoma.
- Since 1993, HBTC has treated more than 8,000 patients with brain tumors, including more than 1,400 patients with glioblastoma, the deadliest form of brain tumors.
- HBTC is a cornerstone for a cutting-edge diagnostic platform which will use genomic profiling to deepen understanding of brain tumors at a core molecular level and foster more informed treatment decisions.

**When Is a Headache Not a Headache?**

It was her worst fear come true. Southfield, Michigan, resident Nestelynn Gay had a brain tumor. It was malignant. And chances for survival weren’t good. Until she came to the Hermelin Brain Tumor Center.

“I think until you face something like this, the thought of brain surgery is very daunting,” she says. “One of the things I appreciate about Henry Ford is the whole team is so hopeful and they’re so positive.”

Henry Ford had the technology required to target Nestelynn’s tumor directly, including intraoperative MRI scanning and functional imaging. The team was able to go in, in real time, and see where the tumor was located, while protecting the normal brain. Surgeons removed her tumor and gave Nestelynn hope for the future.

“I’m very fortunate that … two and a half years after having brain surgery, I’m doing great,” she says. “I’m living my life, and I feel confident that should I need further treatment, I’m in the right place to get it.”

**These Achievements Wouldn’t Be Possible Without Donor Contributions:**

- The number of long-term survivors tripled at HBTC in 15 years (national average doubled).
- 2nd largest tissue bank in the world, a national resource.
- First and only Midwest location providing world-class genomic sequencing for patients.
- Personalized medicine using avatars to evaluate individual tumor function and customize treatment.

Transformation happens every day—and, with your help, for generations to come.